PMID- 34154596
OWN - NLM
STAT- MEDLINE
DCOM- 20210623
LR  - 20210625
IS  - 1477-7819 (Electronic)
IS  - 1477-7819 (Linking)
VI  - 19
IP  - 1
DP  - 2021 Jun 21
TI  - The role of FOLFIRINOX in metastatic pancreatic cancer: a meta-analysis.
PG  - 182
LID - 10.1186/s12957-021-02291-6 [doi]
LID - 182
AB  - BACKGROUND: The prognosis of pancreatic cancer (PC) is extremely poor, and most 
      patients with metastatic PC still receive palliative care. Here, we report the 
      efficacy and safety of FOLFIRINOX (oxaliplatin, irinotecan, leucovorin, 
      5-fluorouracil) in the treatment of metastatic PC. METHODS: We searched PubMed, 
      Web of Science, EBSCO, and Cochrane library databases for articles that described 
      efficacy and safety of FOLFIRINOX in patients with metastatic PC, from January 
      1996 to July 2020. The primary outcomes targeted included overall survival (OS) 
      and progression-free survival (PFS). RESULTS: We found that FOLFIRINOX could 
      directly improve OS rate of patients with metastatic PC (HR 0.76, 95% Cl 
      0.67-0.86, p<0.001) but had no benefit on PFS. Results from subgroup analyses 
      showed that FOLFIRINOX had superior benefits than monochemotherapy (HR 0.59, 95% 
      Cl 0.52-0.67, p<0.001), followed by FOLFIRINOX versus combination chemotherapy 
      (HR 0.76, 95% Cl 0.61-0.95, p<0.001). The result of FOLFIRINOX versus 
      nab-paclitaxel + gemcitabine had no benefit (HR 0.91, 95% Cl 0.82-1.02, p>0.05). 
      The main adverse events (AEs) targeted hematological toxicity and the 
      gastrointestinal system, and included febrile neutropenia, a reduction in white 
      blood cells and appetite, as well as diarrhea. CONCLUSION: These findings 
      indicated that FOLFIRINOX has potential benefits for the prognosis of patients 
      with metastatic PC. Furthermore, there is no difference between the regimen of 
      FOLFIRINOX and nab-paclitaxel + gemcitabine in this study. The application of 
      FOLFIRINOX should be according to the actual situation of the patients and the 
      experience of the doctors.
FAU - Zhang, Beilei
AU  - Zhang B
AD  - The Second Clinical Medical College, Zhejiang Chinese Medical University, 
      Hangzhou, Zhejiang, China.
FAU - Zhou, Fengyan
AU  - Zhou F
AD  - Emergency Medical Center, Ningbo Yinzhou No 2 Hospital, Ningbo, Zhejiang, China.
FAU - Hong, Jiaze
AU  - Hong J
AD  - The Second Clinical Medical College, Zhejiang Chinese Medical University, 
      Hangzhou, Zhejiang, China.
FAU - Ng, Derry Minyao
AU  - Ng DM
AD  - Medical College of Ningbo University, Ningbo, Zhejiang, China.
FAU - Yang, Tong
AU  - Yang T
AD  - Department of Tumor HIFU Therapy, HwaMei Hospital, University of Chinese Academy 
      of Sciences, Ningbo, Zhejiang, China.
FAU - Zhou, Xinyu
AU  - Zhou X
AD  - The Second Clinical Medical College, Zhejiang Chinese Medical University, 
      Hangzhou, Zhejiang, China.
FAU - Jin, Jieyin
AU  - Jin J
AD  - The Second Clinical Medical College, Zhejiang Chinese Medical University, 
      Hangzhou, Zhejiang, China.
FAU - Zhou, Feifei
AU  - Zhou F
AD  - The Second Clinical Medical College, Zhejiang Chinese Medical University, 
      Hangzhou, Zhejiang, China.
FAU - Chen, Ping
AU  - Chen P
AD  - Department of General Surgery, HwaMei Hospital, University of Chinese Academy of 
      Sciences, Ningbo, Zhejiang, China.
FAU - Xu, Yunbao
AU  - Xu Y
AD  - Department of Radiotherapy and Chemotherapy, Hwamei Hospital, University of 
      Chinese Academy of Sciences, Northwest Street 41, Haishu District, Ningbo, 
      315010, Zhejiang, China. chenjj1984no2h@163.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20210621
PL  - England
TA  - World J Surg Oncol
JT  - World journal of surgical oncology
JID - 101170544
RN  - 0 (folfirinox)
RN  - 04ZR38536J (Oxaliplatin)
RN  - 7673326042 (Irinotecan)
RN  - Q573I9DVLP (Leucovorin)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - *Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Fluorouracil/therapeutic use
MH  - Humans
MH  - Irinotecan
MH  - Leucovorin/therapeutic use
MH  - Oxaliplatin/therapeutic use
MH  - *Pancreatic Neoplasms/drug therapy
MH  - Prognosis
PMC - PMC8218408
OTO - NOTNLM
OT  - Efficacy
OT  - FOLFIRINOX
OT  - Meta-analysis
OT  - Metastatic pancreatic cancer
OT  - Safety
COIS- The authors declare that they have no competing of interests.
EDAT- 2021/06/23 06:00
MHDA- 2021/06/24 06:00
PMCR- 2021/06/21
CRDT- 2021/06/22 05:37
PHST- 2021/02/09 00:00 [received]
PHST- 2021/06/04 00:00 [accepted]
PHST- 2021/06/22 05:37 [entrez]
PHST- 2021/06/23 06:00 [pubmed]
PHST- 2021/06/24 06:00 [medline]
PHST- 2021/06/21 00:00 [pmc-release]
AID - 10.1186/s12957-021-02291-6 [pii]
AID - 2291 [pii]
AID - 10.1186/s12957-021-02291-6 [doi]
PST - epublish
SO  - World J Surg Oncol. 2021 Jun 21;19(1):182. doi: 10.1186/s12957-021-02291-6.